Patrick Baeuerle

Patrick Baeuerle

Company: MPM Capital

Job title: Managing Director


Dr. Patrick A. Baeuerle is the co-founder of six MPM oncology start-ups. He has taken on a leadership role in one MPM portfolio company and serves on the board of directors and scientific advisory boards at several other portfolio companies.
Prior to joining MPM, Patrick was Vice President, Research, and General Manager of Amgen Research Munich GmbH, where he was responsible for the development of BiTE antibody Blincyto®, which was approved in 2014 in less than three months by the U.S. FDA for therapy of relapsed/refractory acute lymphoblastic leukemia. He has also served as Chief Scientific Officer for Micromet, Inc., and earlier headed small-molecule drug discovery at Tularik Inc., a publicly traded biotechnology company also acquired by Amgen (AMGN). Prior to this, he was Professor and Chairman of Biochemistry and Molecular Biochemistry at the Medical Faculty of Freiburg University, Germany, where he did groundbreaking research on transcription factor NF-kappaB.
Patrick is the recipient of the European Molecular Biology Laboratory’s 2019 Lennart Philipson Award in recognition of his many contributions to the development of cancer immunotherapies. To date, he has published 240 PubMed-listed papers that have been cited more than 69,800 times. He has a Hirsh index of 126 and was rated Germany’s most frequently cited biomedical scientist of the decade (1990-1999), and among the top 50 worldwide (1990 to 1997).
Patrick holds a Ph.D. in Biology from the University of Munich and performed post-doctoral research with Dr. David Baltimore at the Whitehead Institute at MIT. He is also an Honorary Professor of Immunology of the Medical Faculty at the University of Munich.

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.